Journal of the American Chemical Society
Communication
(
12) For recent examples of 3,4-pyridyne regioselectivities, see:
AUTHOR INFORMATION
(
a) Enamorado, M. F.; Ondachi, P. W.; Comins, D. L. Org. Lett. 2010,
1
2, 4513. (b) Saito, N.; Nakamura, K.-i.; Shibano, S.; Ide, S.; Minami, M.;
Sato, Y. Org. Lett. 2013, 15, 386. (c) Saito, N.; Nakamura, K.-i.; Sato, Y.
Heterocycles 2014, 88, 929.
Author Contributions
T.C.M. and J.M.M. contributed equally.
Notes
(13) Given the widespread use of silyl triflates in aryne and cycloalkyne
trapping experiments (using mild fluoride-based conditions), we
deemed silyl triflate to be 8 an ideal target.
†
(
14) Comins, D. L.; Joseph, S. P.; Goehring, R. R. J. Am. Chem. Soc.
994, 116, 4719.
15) Knapp, S.; Yang, C.; Pabbaraja, S.; Rempel, B.; Reid, S.; Withers, S.
G. J. Org. Chem. 2005, 70, 7715.
The authors declare no competing financial interest.
1
(
ACKNOWLEDGMENTS
■
The authors are grateful to the NIH NIGMS (R01 GM090007 to
N.K.G.), the National Science Foundation (CHE-1361104 to
K.N.H.), Bristol-Myers Squibb, DuPont, the Alfred P. Sloan
Foundation, the S. T. Li Foundation, the Dreyfus Foundation,
the UC Cancer Research Coordinating Committee, and the
UCLA Cota Robles Fellowship Program (J.M.M.) for financial
support. This work used the Extreme Science and Engineering
Discovery Environment (XSEDE), which is supported by the
National Science Foundation (OCI-1053575) along with the
UCLA Institute of Digital Research and Education (IDRE).
These studies were supported by shared instrumentation grants
from the NSF (CHE-1048804) and the National Center for
Research Resources (S10RR025631).
́ ́
(16) Atanes, N.; Escudero, S.; Perez, D.; Guitian, E.; Castedo, L.
Tetrahedron Lett. 1998, 39, 3039.
(
17) Aldrich Chemical Co, Inc. is currently commercializing silyl
triflate 8, which will be available by mid 2015.
18) For entry 6, substantial mass was lost to nonproductive reaction
(
pathways, which may render the regioselectivity data unreliable. In the
case of entry 7, the lack of regioselectivity can be attributed to the
sydnone trappings occurring through concerted, highly synchronous
transition states with low activation barriers. Larock and Shi have
reported similarly modest regioselectivities using 3-methoxybenzyne
with the sydnone trapping agent. See: Fang, Y.; Wu, C.; Larock, R. C.;
Shi, F. J. Org. Chem. 2011, 76, 8840.
(19) Structural similarity searches were performed using SciFinder
Scholar. Other scaffolds, including the minor adduct from the diazo ester
cycloaddition (Table 2, entry 5) and the major product from the
sydnone cycloaddition (Table 2, entry 7) are also difficult to access.
REFERENCES
■
(20) Vaca, M. J. A.; Gil, J. I. A.; Chrovian, C. C.; Coate, H. R.; Angelis,
(
1
1) Vitaku, E.; Smith, D. T.; Njardarson, J. T. J. Med. Chem. 2014, 57,
0257.
M. D.; Dvorak, C. A.; Gelin, C. F.; Letavic, M. A.; Savall, B. M.; Soyode-
Johnson, A.; Stenne, B. M.; Swanson, D. M. P2X7 Modulators. US
(
2) Wentrup, C.; Blanch, R.; Briehl, H.; Gross, G. J. Am. Chem. Soc.
2
(
0140275015, Sept 18, 2014.
21) Ashton, W. T.; Caldwell, C. G.; Mathvink, R. J.; Ok, H. O.; Reigle,
1
988, 110, 1874.
(
(
3) Tlais, S. F.; Danheiser, R. L. J. Am. Chem. Soc. 2014, 136, 15489.
4) Medium-sized N-containing cycloalkynes have been used in
L. B.; Weber, A. E. 3-Amino-4-Phenylbutanoic Acid Derivatives as
Dipeptidyl Peptidase Inhibitors for the Treatment or Prevention of
Diabetes. WO 2004064778, Aug 05, 2004.
bioorthogonal click chemistry by Bertozzi and others. For a pertinent
review, see: Sletten, E. M.; Bertozzi, C. R. Angew. Chem., Int. Ed. 2009,
(22) Thompson, F.; Maillet, P.; Damiano, T.; Cherrier, M. P.; Clerc, F.
4
8, 6974.
New Tetrahydropyrazolo(3,4-c)pyridine Derivatives are Kinase Mod-
ulators Used Especially for Treating Cancer. FR 2857362, Jan 14, 2005.
(
5) Levine, R.; Leake, W. W. Science 1955, 121, 780.
(
(
6) Martens, R. J.; den Hertog, H. J. Tetrahedron Lett. 1962, 3, 643.
7) For recent reviews of arynes and hetarynes, see: (a) Bronner, S. M.;
(23) Blatt, L. M.; Seiwert, S.; Beigelman, L.; Kercher, T.; Kennedy, A.
L.; Andrews, S. W. Novel Inhibitors of Hepatitis C Virus Replication.
WO 2008005511, Jan 10, 2008.
Goetz, A. E.; Garg, N. K. Synlett 2011, 2599. (b) Tadross, P. M.; Stoltz,
B. M. Chem. Rev. 2012, 112, 3550. (c) Gampe, C. M.; Carreira, E. M.
Angew. Chem., Int. Ed. 2012, 51, 3766. (d) Bhunia, A.; Yetra, S. R.; Biju,
A. T. Chem. Soc. Rev. 2012, 41, 3140. (e) Goetz, A. E.; Garg, N. K. J. Org.
Chem. 2014, 79, 846. (f) Goetz, A. E.; Shah, T. K.; Garg, N. K. Chem.
Commun. 2015, 51, 34.
(24) Comparative regioselectivity data for the reactions of 3 and 1a are
summarized below (C4 attack favored in all cases). For piperidyne
regioselectivity data, see Table 2 and the Supporting Information. For
pyridyne regioselectivity data, see ref 8a and: Goetz, A. E.; Garg, N. K.
Unpublished results. For additional pyridyne azide cycloaddition
regioselectivity data, see ref 12c .
(
8) For our laboratories' studies of arynes, heterocyclic arynes, and the
aryne distortion model, see: (a) Bronner, S. M.; Bahnck, K. B.; Garg, N.
K. Org. Lett. 2009, 11, 1007. (b) Cheong, P. H.-Y.; Paton, R. S.; Bronner,
S. M.; Im, G.-Y. J.; Garg, N. K.; Houk, K. N. J. Am. Chem. Soc. 2010, 132,
1
267. (c) Im, G.-Y. J.; Bronner, S. M.; Goetz, A. E.; Paton, R. S.; Cheong,
P. H.-Y.; Houk, K. N.; Garg, N. K. J. Am. Chem. Soc. 2010, 132, 17933.
d) Bronner, S. M.; Goetz, A. E.; Garg, N. K. J. Am. Chem. Soc. 2011, 133,
832. (e) Goetz, A. E.; Bronner, S. M.; Cisneros, J. D.; Melamed, J. M.;
Paton, R. S.; Houk, K. N.; Garg, N. K. Angew. Chem., Int. Ed. 2012, 51,
758. (f) Bronner, S. M.; Mackey, J. L.; Houk, K. N.; Garg, N. K. J. Am.
Chem. Soc. 2012, 134, 13966. (g) Goetz, A. E.; Garg, N. K. Nat. Chem.
013, 5, 54. (h) Medina, J. M.; Mackey, J. L.; Garg, N. K.; Houk, K. N. J.
Am. Chem. Soc. 2014, 136, 15798.
9) For a recent study of cyclohexynes and cyclopentyne, see: Medina,
J. M.; McMahon, T. C.; Jimenez-Oses, G.; Houk, K. N.; Garg, N. K. J.
Am. Chem. Soc. 2014, 136, 14706.
10) The ability to access heterocyclic scaffolds with significant
(
3
(25) Considering the standard error associated with computations and
that the transition states are very early with low barriers, we consider the
computational and experimental findings to be in reasonable accord.
(26) Bent, H. A. Chem. Rev. 1961, 61, 275.
2
2
(
́
́
(
aliphatic character is an important direction in modern drug discovery.
See: (a) Lovering, F.; Bikker, J.; Humblet, C. J. Med. Chem. 2009, 52,
6
752. (b) Ritchie, T. J.; Macdonald, S. J. F. Drug Discovery Today 2009,
1
4, 1011.
(
11) The carboxybenzyl (Cbz) protecting group was chosen because of
its pronounced stability and its ability to be selectively cleaved.
D
J. Am. Chem. Soc. XXXX, XXX, XXX−XXX